New Nasal Vaccine Shows Promise against H5N1 Avian Flu
A team of scientists has developed a novel intranasal vaccine against the H5N1 avian influenza virus, demonstrating a robust immune response and preventing infection in animal models. Published in Cell reports Medicine, the research offers a potential new defense against a virus that poses an increasing threat to global health.
Since its initial detection in the United States in 2014, H5N1 has spread from wild birds to poultry and, more recently, to humans. Over 70 human cases, including two fatalities, have been recorded as 2022, raising concerns about the virus’s potential to mutate and trigger another pandemic. The virus continues to circulate among animals, creating ongoing opportunities for adaptation and potential transmission to humans.
The vaccine, developed by researchers at Washington University in St. louis, utilizes a nasal spray delivery method designed to elicit strong immunity within the respiratory tract. This approach is especially promising as it may offer enhanced protection against transmission by directly targeting the site of initial infection. According to co-author Jacco boon, the vaccine effectively protects against both infection and severe illness.
Current avian flu vaccines, developed using older viral strains, may not provide adequate protection against current variants and have limited availability.The Washington University team leveraged their existing nasal vaccine technology – previously used to create a COVID-19 vaccine currently available in India and undergoing clinical trials in the United States – to address this challenge.
The new vaccine employs an optimized antigen, designed based on shared characteristics of viral proteins, delivered via a harmless, non-replicating adenovirus. This delivery system effectively introduces the antigen to the immune system, prompting a protective response.
Researchers are now planning further studies in animals and human immune tissue models to refine the vaccine and maximize its effectiveness, particularly in individuals with prior seasonal flu vaccinations or previous influenza infections. These ongoing efforts aim to develop a vaccine that provides broad and durable protection against the evolving threat of H5N1 avian flu.
Keep reading